Cempra, Inc. (CEMP)
(Delayed Data from NSDQ)
$2.33 USD
+0.03 (1.09%)
Updated Nov 3, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Melinta Therapeutics, Inc. [CEMP]
Reports for Purchase
Showing records 61 - 80 ( 89 total )
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology: 2H15 Catalysts For Key Stocks From Our Research Universe
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Pipeline in a Product Continues to Steam Ahead
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
2Q15 Preview, All Eyes on Solitaire IV Readout
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Solithromycin Positioned to Eclipse Macrolides in COPD, Target to $56
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Highlights from Management/Investor Meetings, Adding to Focus List
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Pricing Strategy Key to Robust Commercial Launch
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Solitaire-IV Readout (4Q15) Should Position Soli'' as First-Choice Therapy
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Solithromycin''s A Potential Blockbuster in the Making
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D